UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2024

MICROBOT MEDICAL INC.
(Exact name of registrant as specified in its charter)

Delaware	**000-19871**	**94-3078125**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

288 Grove Street, Suite 388
Braintree, MA 02184
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.01 par value	MBOT	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 11, 2024, Microbot Medical Inc. (the "Company") released updated presentation materials, which are expected to be posted on its website on or about September 12, 2024.

The presentation materials will be accessed via the 'Investors' section, under 'IR Resources' and then 'Additional Resources,' of the Company's website at www.microbotmedical.com. The Company is not undertaking to update these presentation materials.

The presentation materials are also furnished as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Presentation Materials
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MICROBOT MEDICAL INC.

By: */s/ Harel Gadot*
Name: Harel Gadot
Title: Chief Executive Officer, President and Chairman

Date: September 11, 2024


microbot
medical
ACCESS-ABILITY FOR ALL™
The LIBERTY system is currently under R&D and is not cleared for marketing or any clinical use in the US and ROW
*** Microbot Confidential ***

DISCLAIMERS

This presentation (together with any oral statements made in connection herewith, the "Presentation"), is provided for informational purposes only and has been prepared to assist interested parties in evaluating Microbot Medical Inc. ("Microbot") and for no other purpose. This Presentation does not constitute or include an offer to sell, or a solicitation of an offer to purchase or subscribe for, securities of any kind, nor shall there be any sale, issuance or transfer of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Any such offer or solicitation will be made only in connection with the delivery of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or exemptions therefrom. No representation, express or implied, is or will be given by Microbot or its affiliates and advisors as to the accuracy or completeness of the information contained in this Presentation. This Presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "forecast," "may," "can," "will," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends that are not statements of historical matters. Such forward-looking statements with respect to revenues, earnings, performance, strategies, timelines, the market, prospects and other aspects of the business of Microbot are based on current expectations that are subject to risks and uncertainties. A number of factors, many of which are outside of the control of Microbot, could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties, including without limitation, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic Surgical System, the outcome of its studies to evaluate the LIBERTY® Endovascular Robotic Surgical System, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, including whether Microbot succeeds in obtaining FDA approval to commence its pivotal study in humans, any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could adversely affect or delay such studies, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, any lingering uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot can be found under the heading "Risk Factors" in Microbot's periodic reports filed with the Securities and Exchange Commission ("SEC"), which are available on the SEC's web site at www.sec.gov. Microbot disclaims any intent or obligation to update these forward-looking statements, except as required by law.

RAS MARKET IS BIG AND GROWING…



Source: GlobalData; Note: Includes Robotic Surgical Systems and Accessories

IS THERE A BLUE OCEAN?

Source: FSI, Robotic Assisted Surgery Landscape, 2024

ENDOVASCULAR IS A CLEAR BLUE OCEAN



Source: FSI, Robotic Assisted Surgery Landscape, 2024

TOTAL ADDRESSABLE MARKET (USA)



USA ENDOVASCULAR MARKET

US Endovascular Market

5M Annual Procedures

- Neuro 210K
- Coronary 2.8M
- Peripheral 2M

Endovascular Anatomy



ATTRACTIVE MARKET

Over $33.5 billion spent annually in the US on endovascular procedures.

- Coronary: $17.7 billion, Neuro: $1.3 billion, Peripheral: $14.5 billion
- Attractive reimbursement

Procedure	CPT Code	Annual Procedures	Procedure Reimbursement	Total Spend
Peripheral Angioplasty	37225	710,000	$ 10,615	$ 7,536,870,100
Coronary Angioplasty	92928	700,000	$ 10,615	$ 7,430,717,000
Coronary Angiogram	93454	2,000,000	$ 2,958	$ 5,916,920,000
Peripheral Angiogram	36253	1,000,000	$ 5,140	$ 5,139,760,000
Structural Heart	MS-DRG 266	100,000	$ 43,935	$ 4,393,500,000
Peripheral Embolization	37243	110,000	$ 10,615	$ 1,167,684,100
Peripheral Thrombectomy	37184	60,000	$ 10,615	$ 636,918,600
Neuro TAE/Thrombo	37243	50,000	$ 10,615	$ 530,765,500
Neuro Angiogram	36223	100,000	$ 5,140	$ 513,976,000
Neuro Shunts	62230	60,000	$ 4,350	$ 261,000,000
		4,890,000		**$ 33,528,111,300**

INITIAL TARGET THERAPIES

- **Peripheral Vascular**
  - Embolotherapy
  - Interventional Oncology
  - MSK
  - Others



UNMET NEEDS

Time To Treatment
(TTT, e.g. "Time Is Brain")

- At the site
- To the site

Radiation Exposure

- Due to the cumulative impact of radiation exposure during their career, HCPs are 3 times more likely to develop cancer and 6 times more likely to develop cataracts

Physical strain
(ergonomics)

- 61% of interventional radiologists experience lower back pain or neck pain

Precisions

- Non-target treatments

Staff Availability

- Lack of efficiencies
- "Radiation sidelined" - Clinicians involved in procedures with radiation exposure are 21% more likely to have missed work due to work-related pain

SUPPORTED BY INTERVENTIONALISTS

Do you anticipate that you will begin using a robotic-assisted vascular intervention system in the future?



N=200 interventionalists, data on file

ENDOVASCULAR ROBOTICS: LIMITED ADOPTION



[1] Deduced from Public Records

THEY STILL TRY TO PLAY THE SAME GAME



"Insanity is doing the same thing over & over again & expecting different results."

Albert Einstein

MULTIPLE BARRIERS LEADING TO LOW PENETRATION

Extended set-up time

Special training, long learning curve

Large footprint

Capital expense

Cumbersome and expensive disposables

Dedicated infrastructure

MULTIPLE BARRIERS LEADING TO LOW PENETRATION


The LIBERTY system is not cleared for marketing or any clinical use


ELIMINATING BARRIERS, ALLOWING ACCESS
microbot
medical

ELIMINATING BARRIERS, ALLOWING ACCESS

Disposable
- No capital expense
- Increases procedure efficiency

Small Footprint
- Compact & Light
- No dedicated infrastructure

Mobile
- Utilized in multiple sites of service

Remote
- Reduce exposure to radiation*
- Eliminate user physical strain*
- Telesurgery enabled

Universal
- Compatible with off-the-shelf instruments

*When operating seated away from radiation source


The LIBERTY system is not cleared for marketing or any clinical use

REDEFINING ROBOTICS BUSINESS MODEL

Disposable

- No upfront capital expense
- Recurring revenue

Capital

- Simpler & faster buying process
- Leverage department OPEX
- Not require special infrastructures
- Fits in any set up (OBL, ASC)
- Multiple-room activation

Service

- Eliminate extensive expense to hire & support service team
- Remove inventory expense for parts

REGULATORY STATUS

510(k) Clearance expected H1 2025

Expected H2 2026

ROAD TO COMMERCIALIZATION

IDE approval to commence pivotal human clinical trial for LIBERTY® Robotic System

Trials

Initiate pivotal human clinical trial for LIBERTY® Robotic System July 2024

Key Opinion Leaders

Continue to engage with Key Opinion Leaders (KOLs) and leading academic centers to educate and raise awareness of the LIBERTY® Robotic System

Commercialization Readiness

Establish a strong network of centers of excellence in US, Europe and Israel in anticipation of commercial launch

IP Portfolio

Expand and protect the Company's global IP portfolio in global jurisdictions, which creates significant barriers to entry

Pipeline Development

Continue developing LIBERTY® ecosystem (remote, autonomous, etc.)

Enhance Core Capabilities

Continue establishing leadership team to support future regulatory and commercial activities

Strategic Collaborations

Continued collaboration for future growth

ACCESS-ABILITY FOR ALL™

NO MATTER WHAT • NO MATTER WHERE • NO MATTER WHO

CONCLUSION

- Endovascular market is very large (~5M procedures in the USA alone)
- Many endovascular procedures are life saving procedures (e.g. stroke)
- Clear unmet needs effect all stakeholders
- Attractive reimbursement
- Limited players with no differentiation and same business model

ACCESS-ABILITY FOR ALL™

The LIBERTY system is currently under R&D and is not cleared for marketing or any clinical use in the US and ROW